Q32 Bio Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $53.7M | $0 | $1.2M | $3.2M | $34.0M |
| Research and development | $19.2M | $48.1M | $31.7M | $98.4M | $93.1M |
| Operating expenses | $36.8M | $66.1M | $41.6M | $136.5M | $129.9M |
| Operating income | $16.9M | -$66.1M | -$48.3M | -$133.3M | -$95.9M |
| Pretax income | $29.8M | -$46.1M | -$53.4M | $1.2M | -$95.8M |
| Income tax expense | $0 | $21,000 | $318,000 | $715,000 | $0 |
| Net income | $29.8M | -$47.7M | -$53.7M | -$5.0M | -$95.8M |
| Balance Sheet | |||||
| Cash and equivalents | $48.3M | $78.0M | $25.6M | $34.0M | $108.4M |
| Current assets | $55.0M | $81.9M | $28.7M | $181.0M | $191.9M |
| Total assets | $61.8M | $92.3M | $47.1M | $228.5M | $211.7M |
| Current liabilities | $11.3M | $16.5M | $14.1M | $22.6M | $17.2M |
| Total liabilities | $19.8M | $86.7M | $118.5M | $50.5M | $42.1M |
| Stockholders' equity | $42.0M | $5.7M | -$182.9M | -$130.7M | $169.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$33.5M | -$67.7M | -$18.7M | -$113.7M | -$109.8M |
| Depreciation and amortization | $391,000 | $487,000 | $499,000 | $1.3M | $8.4M |
| Stock-based compensation | $5.3M | $4.4M | $1.4M | $13.1M | $17.2M |
| Capital expenditure | $0 | $75,000 | $5,000 | $1.3M | $2.4M |
| Free cash flow | -$33.5M | -$67.8M | -$18.7M | -$114.9M | -$112.1M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 17.0M · Free float 0.0%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.